In short
Clinical trials are investigating 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE in people with glioblastoma. The trial data focus on studying treatment benefit, especially overall survival, and on finding patient groups or biomarkers that may respond better. The main target population is patients with newly diagnosed or recurrent glioblastoma.
Key points
- Clinical trial data for 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE focus on glioblastoma, a serious brain cancer. The study includes patients with newly diagnosed and recurrent disease. It is a Phase 4 interventional trial with a large planned enrollment of 1845 people. The main outcome is overall survival, measured from randomization to death from any cause. The trial also looks for patient subtypes and biomarkers that may help identify who benefits most from treatment.
Trial overview
The available trial data describe one interventional study in glioblastoma, a type of brain cancer. The study is authorised and planned for 1845 participants.
This trial is designed to test multiple treatment regimens and to see whether any of them improve patient outcomes in newly diagnosed and recurrent glioblastoma.
Who is being studied
The target population includes people with glioblastoma (GBM), including those who are newly diagnosed and those whose disease has returned. The source data do not list detailed age limits, lab requirements, or other eligibility rules.
In simple terms, this means the study is focused on patients with a serious brain tumor, not on healthy volunteers.
Study design and phase
The study is listed as Phase 4, which usually means the treatment is being studied in a larger real-world patient group after earlier research stages. The trial also uses a screening stage and an expansion stage.
In the screening stage, researchers look for experimental therapies that may improve overall survival. In the expansion stage, they confirm the most promising therapies and the biomarker patterns linked with benefit.
Treatments and comparisons
The trial data list several study drugs: ADI-PEG-20, Troriluzole, and AZD1390. These are being tested as part of multiple regimens, meaning different treatment plans are being compared within the study.
The source does not provide a full description of all study groups or how each regimen is assigned, so only the listed trial information can be confirmed.
Main endpoint and what it means
The primary endpoint is overall survival, defined as the time from randomization until death from any cause. This is one of the most important measures in cancer trials because it shows whether a treatment helps patients live longer.
Randomization means patients are assigned to a study group by chance, which helps make the groups more fair for comparison.
Biomarkers and patient subgroups
The study aims to identify patient subtypes or biomarkers that may be linked to better benefit from treatment. A biomarker is a measurable sign in the body that may help researchers understand disease behavior or treatment response.
This means the study is not only asking whether a treatment works, but also which patients may be most likely to benefit.
Trial summary
In summary, the trial data for 7-FLUORO-3-METHYL-8-[6-(3-PIPERIDIN-1-YLPROPOXY)PYRIDIN-3-YL]-1-PROPAN-2-YLIMIDAZO[4,5-C]QUINOLIN-2-ONE are centered on glioblastoma research. The study is authorised, Phase 4, and planned for a large group of 1845 patients. Its main goal is to improve overall survival and to confirm which patient groups and biomarkers are linked to benefit.